Mupirocin
Monoxycarbolic acid
Streptococcus spp., Staphylococcus spp., H. influenzae,
M. catarrhalis, Neisseria spp., P. multocida
Protein synthesis interruption by inhibition of isoleucine
incorporation into growing bacterial protein chain.
Pharmacodynamics:
No data
Protein binding: 95%
Serum half-life: 20-35 minutes
Nares: local irritation, rhinitis
Skin: Rash, purities, headache
Other: taste alterations
Mupirocin Nasal Ointment (Parafin based) (1g)
Mupirocin Ointment (15, 30g)
Muprocin Ointment (Polyethylene glycol based) (22g)
Impetigo: Apply to affected area q 8 hours for 3 to 5 days
Nasal decolonization of MRSA: Apply to nares q 12h for 5
days
Disease state based dosing:
Renal failure: Dosing adjustments not necessary
Hepatic failure: Dosing adjustments not necessary
Contraindications/Warnings/Precautions:
Precautions:
- Polyethylene glycol may be absorbed systemically if
applied to open wounds
No data available
Pregnancy:
Category B: No evidence of risk in humans
but studies inadequate.
Patients should
be monitored for symptoms of local irritation.
No laboratory
parameters exist to monitor for efficacy or toxicity
Brand names/Manufacturer:
- BACROCIN (ICN - BRAZIL)
- BACTODERM (Agis - ISRAEL)
- BACTROBAN (SmithKline
Beecham – USA, CANADA, UK, IRELAND, NETHERLANDS, SOUTH AFRICA, FRANCE,
BELGIUM, SPAIN, SWEDEN, AUSTRIA, SWITZERLAND, ITALY, AUSTRALIA, DENMARK,
BRAZIL, JAPAN, HONG KONG, MEXICO, ISREAL, THAILAND, SINGAPORE, FINLAND, NEW
ZEALAND, MALAYSIA, PORTUGAL, GREECE, CHILE, HUNGARY, CZECH REPUBLIC)
- BACTRONEO (Neo Quimica - BRAZIL)
- CELEFER (Smith Kline - Spain)
- CENTANY (Ortho - USA)
- EISMYCIN (GlaxoSmithKline
- GERMANY)
- EISMYCIN (SmithKline - GERMANY)
- HEVRONAZ (Rafarm - GREECE)
- INFECTOPYODERM (Infectopharm
- GERMANY)
- MICOBAN (Genepharm - GREECE)
- MUPIDERM (Pharmafarm -
FRANCE)
- MUPIROCIN (Teva - USA)
- MUPORIN (TO-Chemicals - THAILAND)
- PLASIMINE (Isdin - SPAIN)
- TURIXIN (GlaxoSmithKline - GERMANY)
- ULTRABIOTIC (Bago - CHILE)
- UNDERAN (Saval - CHILE)
- VELTION (Faran - GREECE)